House File 2042 - Introduced

HOUSE FILE 2042 BY ISENHART

A BILL FOR

- 1 An Act relating to the information provided a patient prior
- 2 to prescribing a controlled substance for acute or chronic
- 3 pain.
- 4 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:

H.F. 2042

- 1 Section 1. <u>NEW SECTION</u>. 124.559 Provision of information 2 prescribing of controlled substances for acute or chronic pain.
- 3 1. Prior to issuing an initial prescription for a schedule
- 4 II controlled substance or any other prescription opioid in a
- 5 course of treatment for acute or chronic pain, and again prior
- 6 to issuing the third prescription in the course of treatment,
- 7 a prescribing practitioner shall discuss with the patient,
- 8 or the patient's parent or quardian if the patient is under
- 9 eighteen years of age and is not an emancipated minor, the
- 10 risks associated with the substance being prescribed, including
- 11 but not limited to:
- 12 a. The risks of addiction and overdose associated with
- 13 opioid drugs and the dangers of taking opioid drugs with
- 14 alcohol, benzodiazepines, and other central nervous system
- 15 depressants.
- 16 b. The reasons why the prescription is necessary.
- 17 c. Alternative treatments that may be available.
- 18 d. The risks associated with the use of the substance
- 19 being prescribed, specifically that opioids are highly
- 20 addictive, even when taken as prescribed, that there is a
- 21 risk of developing a physical or psychological dependence on
- 22 the substance and that the risks of taking more opioids than
- 23 prescribed, or mixing sedatives, benzodiazepines or alcohol
- 24 with opioids, can result in fatal respiratory depression.
- 25 2. The prescribing practitioner shall include a note
- 26 in the patient's medical record that the patient or the
- 27 patient's parent or quardian, as applicable, has discussed
- 28 with the practitioner the risks of developing a physical or
- 29 psychological dependence on the prescribed substance and
- 30 alternative treatments that may be available.
- 31 3. This section shall not apply to a prescription for the
- 32 substances specified for a patient who is currently in active
- 33 treatment for cancer or receiving hospice or palliative care
- 34 through a hospice program as defined in section 135J.1, for the
- 35 resident of a long-term care facility, or to any substances

H.F. 2042

- 1 that are being prescribed for use in the treatment of substance 2 use disorder or opioid dependence.
- 3 4. As used in this section:
- 4 a. "Long-term care facility" means the same as defined in 5 section 231.4.
- 6 b. "Prescribing practitioner" means the same as defined in 7 section 124.550.
- 8 Sec. 2. CODE EDITOR DIRECTIVE. The Code editor shall
- 9 designate section 124.559, as enacted in this Act, as a new
- 10 subchapter within chapter 124.
- 11 EXPLANATION
- The inclusion of this explanation does not constitute agreement with the explanation's substance by the members of the general assembly.
- 14 This bill relates to the information to be provided by a
- 15 prescribing practitioner to a patient prior to the prescribing
- 16 of a controlled substance for acute or chronic pain. The bill
- 17 provides that prior to issuing an initial prescription of a
- 18 schedule II controlled substance or any other prescription
- 19 opioid in a course of treatment for acute or chronic pain, and
- 20 again prior to issuing the third prescription in the course of
- 21 treatment, a prescribing practitioner shall discuss with the
- 22 patient, or the patient's parent or guardian if the patient
- 23 is under 18 years of age and is not an emancipated minor, the
- 24 risks associated with the substance being prescribed. The
- 25 information to be discussed includes but is not limited to:
- 26 the risks of addiction and overdose associated with opioid
- 27 drugs and the dangers of taking opioid drugs with alcohol,
- 28 benzodiazepines, and other central nervous system depressants;
- 29 the reasons why the prescription is necessary; alternative
- 30 treatments that may be available; and the risks associated with
- 31 the use of the substance being prescribed. The prescribing
- 32 practitioner shall include a note in the patient's medical
- 33 record that the patient or the patient's parent or guardian,
- 34 as applicable, has discussed with the practitioner the risks
- 35 of developing a physical or psychological dependence on the

H.F. 2042

- 1 prescribed substance and alternative treatments that may be
- 2 available. The bill does not apply to a prescription for
- 3 the substances specified in the bill for a patient who is
- 4 currently in active treatment for cancer or receiving hospice
- 5 or palliative care through a hospice program, for the resident
- 6 of a long-term care facility, or to any substances that are
- 7 being prescribed for use in the treatment of substance use
- 8 disorder or opioid dependence.